Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling

This is a preview of subscription content, access via your institution.

References

  1. 1.

    National Institute for Health and Care Excellence. Final appraisal determination. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. National Institute for Health and Care Excellence. 2015. Available at: https://www.nice.org.uk/guidance/TA375/documents/rheumatoid-arthritis-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-abatacept-and-tocilizumab-review-id537-final-appraisal-determination-document2. Accessed 19 Apr 2017.

  2. 2.

    Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, et al. Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. Eur J Health Econ. 2016;17:755–70.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Chilcott J, McCabe C, Tappenden P, O’Hagan A, Cooper NJ, Abrams K, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326:522 (discussion 522).

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20:S5–26.

    Article  PubMed  Google Scholar 

  5. 5.

    Arnold RJG, Ekins S. Time for cooperation in health economics among the modelling community. PharmacoEconomics. 2010;28:609–13.

    Article  PubMed  Google Scholar 

  6. 6.

    Payne KA, Varon SF, Kawata AK, Yeomans K, Wilcox TK, Manack A, et al. The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics. Cephalalgia. 2011;31:1116–30.

    Article  PubMed  Google Scholar 

  7. 7.

    Afzali HHA, Karnon J. Addressing the challenge for well informed and consistent reimbursement decisions. PharmacoEconomics. 2011;29:823–5.

    Article  Google Scholar 

  8. 8.

    Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A. Modelling comparative efficacy of drugs with different survival profiles: ipilimumab, vemurafenib and dacarbazine in advanced melanoma. BioDrugs. 2016;30:307–19.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    National Institute for Health and Care Excellence. Final evaluation determination: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. 2016. Available at: https://www.nice.org.uk/guidance/HST3/documents/final-evaluation-determination-document. Accessed 19 Apr 2017.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Anthony J. Hatswell.

Ethics declarations

Anthony J. Hatswell is an employee of BresMed Health Solutions, and Fleur Chandler is an employee of GlaxoSmithKline.

Funding

No funding was received for this manuscript

Conflicts of interest

Anthony J. Hatswell and Fleur Chandler declare no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hatswell, A.J., Chandler, F. Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling. PharmacoEconomics 35, 755–757 (2017). https://doi.org/10.1007/s40273-017-0516-2

Download citation

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Psoriasis
  • Multiple Myeloma
  • Muscular Dystrophy
  • Vemurafenib